In subjects with T2DM, weekly administration of tirzepatide at doses of 5 mg, 10 mg, or 15 mg was associated with greater weight loss compared to placebo (− 6.3 kg, − 8.4 kg, and − 9.4 kg, respectively), and 1.7 kg, 4.8 kg, and 7.2 kg greater weight loss compared to selective GLP-1 receptor agonists, demonstrating a dose-dependent effect sustained for up to 2 years [48]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.